Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1Genitourinary 1CNS 1Breast 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Penile Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Melanoma 1Head and Neck Neoplasms 1Colonic Neoplasms 1Castration Resistant Prostate Cancer 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Anus Neoplasms 1

Interventions

pembrolizumab 75Nivolumab 46Cyclophosphamide 25aldesleukin 23fludarabine 16atezolizumab 15Ipilimumab 15Interleukin-2 14Radiosurgery 13Paclitaxel 13Specimen Handling 12Magnetic Resonance Spectroscopy 11Carboplatin 11fludarabine phosphate 9Docetaxel 9durvalumab 8Cisplatin 8cemiplimab 7Bevacizumab 7Radiotherapy 6Gemcitabine 6Biopsy 6spartalizumab 5avelumab 5Pemetrexed 5Oxaliplatin 5Immune Checkpoint Inhibitors 5Filgrastim 5Cryosurgery 5Blood Specimen Collection 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × bintrafusp alfa protein, human × Genitourinary × Clear all
NCT04648826 2021-12-17

Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
DermatologicGenitourinarySarcoma

Carcinoma, Renal Cell, Melanoma, Neoplasms, Germ Cell and Embryonal, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡